San Diego, CA (PRWEB) May 01, 2013
Resource4thePeople announced today that it is informing consumers that a jury has awarded a California man $6.5 million in damages in the first trial* in the country over allegations that Takeda Pharmaceutical’s diabetes drug Actos can cause bladder cancer.
The jury in the Los Angeles Superior Court trial deliberated for more than five days before returning its verdict in favor of Jack Cooper, a 79-year-old man who treated his diabetes with Actos for more than four years before being diagnosed with bladder cancer in 2011, according to testimony presented by his attorneys at the trial.*
Bloomberg News reported** April 12 that Cooper’s lawyers argued that Takeda failed to adequately warn patients, doctors and government regulators about the possibility of the medication causing cancer.
“This is an important case for consumers who have been following the progress of more than 3,000 lawsuits alleging that long-term use of Actos may cause bladder cancer,” said Resource4thePeople.
“Because of this verdict we are anticipating an increased volume of inquiries from consumers about the legal options they may have involving the long-term use of Actos.
“Therefore, our national network of attorneys will continue to offer free consultations to consumers who wish to be informed about their legal rights in cases in which they may have suffered serious side effects from the use of Actos.”
Resource4thePeople said that Actos patients are also inquiring about whether they are still eligible to file a lawsuit even though there has been a verdict in the first trial in the litigation.*
“The answer is yes, and those who wish to obtain a consultation with an experienced Actos bladder cancer lawyer for an evaluation of what compensation and legal options may be available to them should use the following link,” said Resource4thePeople.
In the Los Angeles trial, Bloomberg News reported** that Takeda faces more than 3,000 suits alleging Actos caused bladder cancer or other ailments, according to court records. Cooper’s suit was among those gathered before Judge Kenneth Freeman in Los Angeles. Other cases are in federal court in Louisiana.***
“More than 1,200 suits have been consolidated before a federal judge in Louisiana for pretrial information exchanges,” Bloomberg reported. “The first federal case is set for trial in January, according to court filings.”
Cooper is a retired telephone company worker who, according to the Bloomberg report, had his case “heard on an expedited basis” after the judge found that Cooper is gravely ill.
Bloomberg also reported that Cooper’s lawyer “told jurors that while Takeda’s own research found links between Actos and bladder cancer as early as 2004, company officials didn’t tell regulators about the findings for seven years.”
The lawyers showed jurors internal Takeda email messages in which executives urged colleagues to persuade the U.S. Food and Drug Administration not to demand increased warnings about bladder cancer on Actos’ label out of fear that sales would drop, according to the Bloomberg report.
The Los Angeles trial is one component of the Actos bladder cancer litigation. As this case proceeds other federal court cases that have been consolidated into a federal multi-district litigation are still pending.***
Multi-district litigations are designated by a special federal panel that chooses a single judge to oversee pre-trial evidence-gathering and other legal activities before deciding whether to grant such cases class-action status.
That judge, U.S. District Judge Rebecca Doherty, has scheduled the first bellwether trial in that litigation to be held in November. Bellwether trials are scheduled to allow attorneys for the plaintiffs and defendants to test the strength of their cases.
Concerns about Actos were raised by the U.S. Food and Drug Administration in 2011 after the agency staff reviewed a Takeda-sponsored study which documented an increased risk of developing bladder cancer with Actos than other diabetes drugs.****
Here is part of the safety announcement:
“The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer.”
“Consumers and diabetes patients should also be aware of the fact that in this health warning the FDA noted that Actos has been pulled from the pharmacy shelves in France and Germany but has not been recalled in the United States,” said Resource4thePeople.
Another important finding from medical research, according to Resource4thePeople, comes from the findings of a study recently published in Diabetic Medicine, which also links the use of Actos (pioglitazone) to increased risk of bladder cancer.*****
The findings were based on independent research and data from six other studies that included information taken from more than 215,000 diabetes patients.
The authors of the study reached the following conclusion, according to an abstract of the study:
“Pioglitazone use is associated with an increased risk of bladder cancer. Clinicians must consider this increased risk in the context of the baseline risk for bladder cancer of their patients, other adverse features of this medicine (e.g. weight gain, cost) and its potential anti-hyperglycaemic benefits.”
*Cooper v. Takeda Pharmaceuticals America, Inc., CGC-12-518535, California Superior Court (Los Angeles)
*** In Re: Actos (Pioglitazone) Products Liability Litigation, MDL2299 U.S. District Court, Western District of Louisiana